Results 141 to 150 of about 3,260 (169)

Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist

Experimental Hematology, 2005
Peptide and other small molecule agonists have been described for several cytokines and growth factors. Hydrazone compounds described here as thrombopoietin receptor agonists were identified as activating STAT proteins in a Tpo responsive cell line.STAT activation and analysis of signal transduction pathways in cell lines and normal human platelets was
Connie L, Erickson-Miller, Evelyne, DeLorme, Shin-Shay, Tian, Christopher B, Hopson, Kenneth, Stark, Leslie, Giampa, Elizabeth I, Valoret, Kevin J, Duffy, Juan L, Luengo, Jon, Rosen, Stephen G, Miller, Susan B, Dillon, Peter, Lamb   +12 more
openaire   +2 more sources

Cytomegalovirus‐associated thrombocytopenia treated with thrombopoietin receptor agonist

Internal Medicine Journal, 2016
Symptomatic cytomegalovirus (CMV) in immunocompetent individuals is an uncommon, yet recognised, phenomenon. This report discusses a case of CMV‐associated thrombocytopenia refractory to immunomodulation and antivirals. Ultimately, a clinicopathological response was attained with eltrombopag.
J. D. Simpson, G. V. Matthews, T. A. Brighton, J. E. Joseph   +3 more
openaire   +2 more sources

Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine

Science, 1997
Two families of small peptides that bind to the human thrombopoietin receptor and compete with the binding of the natural ligand thrombopoietin (TPO) were identified from recombinant peptide libraries. The sequences of these peptides were not found in the primary sequence of TPO.
S E, Cwirla, P, Balasubramanian, D J, Duffin, C R, Wagstrom, C M, Gates, S C, Singer, A M, Davis, R L, Tansik, L C, Mattheakis, C M, Boytos, P J, Schatz, D P, Baccanari, N C, Wrighton, R W, Barrett, W J, Dower   +14 more
openaire   +2 more sources

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies

Pediatric Blood & Cancer
ABSTRACTBackgroundThrombopoietin receptor agonists (TPO‐RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy‐induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (AYA) patients with hematologic malignancies are limited ...
Amanda E. Marinoff, Allyson Thrall, Kathryn Aaronson, Benjamin S. Braun, Maria I. Castellanos, Julia Chu, Michelle Hermiston, Benjamin J. Huang, Anya Levinson, Erica Southworth, Beth Apsel Winger, Adam Olshen, Elliot Stieglitz   +12 more
openaire   +2 more sources

Therapeutic Use of Thrombopoietin Receptor Agonists

2017
Discoveries throughout the twentieth century have forged our understanding of platelet production and including the variables involved in regulating the growth and maturation of megakaryocytes (Kuter, Br J Haematol 165:248–58, 2014). Thrombopoietin (TPO) is the premier growth factor involved in platelet production.
Michael D. Tarantino, Sarah Chalmers
openaire   +1 more source

Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia

The Lancet Haematology, 2022
Maria L, Lozano, Francesco, Rodeghiero
openaire   +2 more sources

The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag

Blood Reviews, 2022
David Kuter
exaly  

Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)

Platelets, 2020
John Semple, Rick Kapur, Johan Rebetz
exaly  

Thrombopoietin-receptor agonists in children with immune thrombocytopenia

The Lancet, 2015
Cindy E, Neunert, Rachael F, Grace
openaire   +2 more sources

Proteomic changes by radio-mitigative thrombopoietin receptor agonist romiplostim in the blood of mice exposed to lethal total-body irradiation

International Journal of Radiation Biology, 2020
Yota Tatara, Ikuo Kashiwakura
exaly